نتایج جستجو برای: chronic lymphocytic leukemia

تعداد نتایج: 733768  

2013
Jeffrey Cossman Leonard M. Neckers Rita M. Braziel Jane B. Trepel Ajay Bakhshi

As bstract. B cell chronic lymphocytic leukemia (CLL) cells appear to be arrested in their differentiation so that little immunoglobulin is secreted in most cases. To determine their capacity for further differentiation we stimulated cells from a series of 10 cases of CLL with a phorbol ester and assayed for production of immunoglobulin protein, accumulation of immunoglobulin mRNA, and alterati...

2014
Maliha Khan Areeba Saif Steven Sandler Aibek E Mirrakhimov

Chronic lymphocytic leukemia is the most common leukemia in the United States. It is a slowly progressive disease, with an 82% five-year survival rate. The treatment strategies are highly individualized with patients in the early and stable stages typically not requiring treatment. However, those with progressive or clinically advanced disease will require treatment. Cytotoxic drugs, such as th...

Journal: :Annals of clinical and laboratory science 1982
A Castella F R Davey A S Kurec N A Thompson

The presence of terminal deoxynucleotidyl transferase (TdT) has been determined in neoplastic cells from 50 patients with non-hematologic tumors as well as neoplastic cells from 85 patients with hematologic malignancies. The results indicate that TdT is not present in cells from non-hematologic tumors, Hodgkin's lymphoma, B cell lymphoproliferative disorders, peripheral T cell neoplasms, reacti...

2015
Carol Moreno Marco Montillo Panayiotis Panayiotidis Maria Dimou Adrian Bloor Jehan Dupuis Anna Schuh Stefan Norin

achieves higher surface density, efficiently activates in vitro complement-dependent cytotoxicity (CDC), and shows improved antibody-dependent cell-mediated phagocytosis (ADCC) even when the CD20 expression is low. The results of a pivotal study10 led to the approval of ofatumumab in October 2009 by the US Food and Drug Administration (FDA) for the treatment of CLL refractory to both fludarabin...

2014
Omar Perbellini Erika Falisi Ilaria Giaretta Elisa Boscaro Elisabetta Novella Monica Facco Stefania Fortuna Silvia Finotto Eliana Amati Francesco Maniscalco Anna Montaldi Alberta Alghisi Fiorenza Aprili Laura Bonaldi Rossella Paolini Maria Teresa Scupoli Livio Trentin Achille Ambrosetti Gianpietro Semenzato Giovanni Pizzolo Francesco Rodeghiero Carlo Visco

expressed in early stages of CLL than in advanced CLL and that its expression is lower in patients with high-risk CLL. The association of LAIR1 expression with commonly recognized clinical and biological variables, and its prognostic role in patients with CLL is still unknown. In this study we analyzed LAIR1 expression in a prospective cohort of 311 unselected CLL patients consecutively enrolle...

Journal: :CA: a cancer journal for clinicians 1977
A Manoharan

Chronic lymphocytic leukemia is a neoplasm characterized by the accumulation of monoclonal lymphocytes in blood, bone marrow, and other tissues. Staging of the disease is based on lymphoid mass and the presence of anemia or thrombocytopenia, with prognosis also related to the pattern of bone-marrow involvement, chromosomal abnormalities, and surface membrane phenotype. Transformation to a diffu...

Journal: :The oncologist 1971
J Chauvergne B Hoerni J Touchard G Simon

The diagnosis and management of chronic lymphocytic leukemia (CLL) is reviewed, including the basic aspects of epidemiology, molecular biology, and cytogenetics with clinical relevance. The importance of immunophenotype in the differential diagnosis of other lymphoproliferative disorders related to CLL, staging, prognostic factors, promising new drugs, and approaches is summarized.

Journal: :Current opinion in hematology 1997
T J Kipps

Recent studies have improved our understanding of the cytogenesis, biology, and therapy of chronic lymphocytic leukemia (CLL). This review highlights this recent progress reported over the past year. We have improved our understanding of the cytogenetic abnormalities in CLL and soon may see identification of new tumor suppressor genes that may be deleted in the leukemia cells of a large number ...

Journal: :American family physician 1988
L E Johnson

Although the most rapidly growing portion of the United States population is the elderly, they are consistently underrepresented in clinical cancer trials. The incidence of chronic lymphocytic leukemia (CLL) is markedly increased in older people, with a median age at diagnosis of 72 years. In fact, 75% of CLL patients in the United States are over the age of 65 years and 50% are over the age of...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2010
Michael Hallek Natali Pflug

The management of chronic lymphocytic leukemia (CLL) is currently undergoing a profound change. First, several new drugs have been approved (fludarabine, bendamustine and two monoclonal antibodies, alemtuzumab and rituximab). In addition, novel monoclonal antibodies targeting CD20, CD23, CD37 or CD40, as well as drugs designed to interfere with central pathways regulating the cell cycle, the ap...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید